-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As an emerging biosimilar market, China is rapidly developing into a biotechnology powerhouse. Single Use technology is critical for its flexibility and efficiency in the development and manufacture of biosimilars.
, a leading technology company, announced that it would continue to invest more in China to speed up the ® of Mobius's single-use technology products in Wuxi, the company said in a news report.
announced in November 2016 that it would invest 80 million euros in Nantong, China, to build a life sciences center to help develop its life sciences business in China.
this investment represents Merck's commitment to China and will provide customers and partners in China with a wide range of world-leading and innovative solutions to meet China's fast-growing biopharmaceutical market. The site is located at Merck's Wuxi plant in China, and the construction of a ® production site in Mobius will be completed in the second half of 2018.
recently, Merck announced an additional investment of about 40 million euros in Asia, with life sciences production and distribution bases in South Korea and India and a new one-time technology production base in China.